Myelodysplastic neoplasm with low blasts and isolated 5q deletion

Bone marrow is the tissue inside bones that makes blood. In a myelodysplastic neoplasm the marrow keeps working — often working hard — but the cells it produces are faulty and half-finished, and most of them are destroyed in the marrow or shortly after reaching the bloodstream. The result is a busy factory and an empty blood count.

“Dysplasia” is the word for how those cells look down a microscope: misshapen and immature. It describes appearance, not danger.

The 2022 WHO classification renamed these from “myelodysplastic syndromes” to “myelodysplastic neoplasms”. The abbreviation MDS did not change. The rename matters, because a neoplasm is a cancer in its own right — these are not a waiting room for one.

This subtype is defined by a genetic finding rather than by a cell count: a missing chunk from the long arm of chromosome 5, written as del(5q). “Isolated” means it is essentially the only chromosome abnormality present. The blast count here sits below the raised thresholds, which is what “low blasts” refers to.

The underlying event is a change acquired in a single blood-forming stem cell during a person’s life. It is not inherited from a parent and it cannot be passed to anyone.

For most people no cause is ever identified. That is the most important sentence in this section, and it comes first for a reason — people look hard for something they could have done differently.

Recognised risk factors do exist: previous chemotherapy or radiotherapy for another cancer, exposure to tobacco smoke, pesticides, and solvents such as benzene, some heavy metals, and increasing age. Age is the dominant one.

Nothing in the sources we read supports a lifestyle, diet, stress or emotional cause.

The immediate harm is a shortage of working blood cells. Too few red cells brings fatigue, breathlessness and pallor. Too few neutrophils brings repeated or severe infections. Too few platelets brings easy bruising, bleeding, and pinpoint red spots under the skin.

There are two separate dangers here and it helps to keep them apart. One is the shortage itself, which can be disabling or dangerous on its own. The other is transformation into acute myeloid leukemia. Many people are harmed by the first without ever reaching the second.

That transformation is conventionally marked at 20% blasts — the youngest, most immature cells in the marrow. It is a classification boundary rather than a moment a person feels.

This subtype is typically dominated by anemia and a long-running need for transfusions rather than by an imminent risk of transformation to leukemia. “Typically” is carrying real weight in that sentence — the risk score, not the subtype name, is what classifies any individual.

The goal in lower-risk disease is usually to correct the blood counts and protect quality of life, rather than to eradicate the abnormal cells. That is worth stating plainly, because readers reasonably assume any cancer treatment aims at cure.

Supportive care is real treatment rather than the absence of it: red cell and platelet transfusions, and drugs that prompt the marrow to make more red cells.

This subtype has something the others do not — lenalidomide, an oral drug licensed specifically for transfusion-dependent anemia in lower-risk MDS with a 5q deletion. It is aimed at the defining genetic change.

It is not a gentle drug. It carries a boxed warning covering harm in pregnancy, effects on blood counts, and blood clots in veins and arteries. In the study that led to its approval the dose was reduced or interrupted at least once for a side effect in 118 of 148 people, and blood counts are checked weekly for the first eight weeks.

Iron overload becomes the long-running issue for anyone transfused repeatedly, because the body has no way to excrete the iron that transfusions bring. Chelation drugs remove it — and the NCI is explicit that the effect of chelation on survival and disease progression is unknown. It manages a consequence of transfusion, not the MDS itself.

Clinical trials are a standard option at every risk level, not a last resort.

Most people meeting this diagnosis are in their seventies. Many arrive at it sideways, through a blood test done for something else showing an anemia that will not respond to the usual explanations.

The daily reality is fatigue and a calendar. Transfusion appointments, blood counts, clinic reviews — a rhythm rather than a crisis, running for years.

Fatigue from chronic anemia is consistently underestimated by everyone who does not have it. It is not tiredness that a good night fixes.

The disease is not fixed either. A person in a lower-risk band can move if the disease progresses, or if particular features appear — transfusions stopping working, scarring in the marrow, or new genetic changes. That possibility is a reason for continued monitoring rather than for alarm.

For very low and low risk MDS, EBMT grades a transplant as generally not recommended — and grades it that way from every donor type, matched sibling and unrelated donor alike. Retrospective studies found that people with lower-risk disease do not benefit from an upfront transplant.

So the honest answer for most people reading this page is that a donor is not part of the route, and we are not going to suggest otherwise.

There are two things that are true and worth saying anyway. The first is about the future: some people with lower-risk disease do acquire a transplant indication later, if the disease progresses or if particular high-risk features appear. The second is about other people: a registry someone joins serves everyone with a higher-risk blood cancer, most of whom are not on this page.

Neither of those is a reason to tell a reader here that their own subtype puts them in line for a donor. It does not.